Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRX530)

• Drug Name: TAS-116 Drug Info
• Synonyms: Tas-116; 1260533-36-5; UNII-PLO044MUDZ; PLO044MUDZ; SCHEMBL2694525; CHEMBL3661115; BDBM126083; ZINC169703510; KB-334563; US8779142, 102; Benzamide, 3-ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)-; 3-ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide; 3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 67501411
  CAS Number: CAS 1260533-36-5
  TTD Drug ID: DMRX530

Molecule-Related Drug Atlas

Drug(s) Targeting Heat shock protein 90 beta (HSP90B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SNX-5422	DMIU0VP	Haematological malignancy	2B33.Y	Phase 1/2	[1]
PU-H71	DMIYHAW	Breast cancer	2C60-2C65	Phase 1	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 90 beta (HSP90B)	TTH5YN2	HS90B_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)